Microcap Opportunities

Microcap Opportunities

Share this post

Microcap Opportunities
Microcap Opportunities
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sergio Heiber's avatar
Sergio Heiber
Sep 09, 2024
∙ Paid
1

Share this post

Microcap Opportunities
Microcap Opportunities
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
1
Share

Gossamer Bio (GOSS) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib. Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinica…

Keep reading with a 7-day free trial

Subscribe to Microcap Opportunities to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 MicroCap Opportunities
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share